Search - tctmd.com

Displaying 521 - 540 of 593

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2016

Shelley Wood

April 29, 2016

News Daily News

No More Niacin, Fibrate Combinations With Statins: FDA

Michael O'Riordan

April 19, 2016

News Daily News

Statin Therapy Alters Composition of Coronary Plaques, Virtual Histology-IVUS Study Shows

Michael O'Riordan

April 14, 2016

News Conference News ACC 2016

STEPATHLON: A Mobile-Based Exercise Program Increased Physical Activity and Promoted Weight Loss

Michael O'Riordan

April 04, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Michael O'Riordan

April 02, 2016

News Daily News

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

Michael O'Riordan

March 07, 2016

News Daily News

Elevated LDL Cholesterol in Mom, Increased LDL Cholesterol in Adult Offspring, Irrespective of Genetics

Michael O'Riordan

March 01, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

February 04, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2016

Shelley Wood

February 01, 2016

News Daily News

‘Negative’ Atherosclerotic Imaging Results Shift 10-Year CVD Risk Downward: MESA Analysis

Michael O'Riordan

January 28, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

News Daily News

Refreshed Dietary Guidelines Shift Focus to Healthy Eating Patterns

Todd Neale

January 18, 2016

News Daily News

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Michael O'Riordan

January 12, 2016

Advertisement

TCTMD’s Top 10 Most Popular Stories for April 2016

No More Niacin, Fibrate Combinations With Statins: FDA

Statin Therapy Alters Composition of Coronary Plaques, Virtual Histology-IVUS Study Shows

STEPATHLON: A Mobile-Based Exercise Program Increased Physical Activity and Promoted Weight Loss

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Elevated Triglycerides Linked to All-Cause Mortality and Coronary Artery Disease

Elevated LDL Cholesterol in Mom, Increased LDL Cholesterol in Adult Offspring, Irrespective of Genetics

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

TCTMD’s Top 10 Most Popular Stories for January 2016

‘Negative’ Atherosclerotic Imaging Results Shift 10-Year CVD Risk Downward: MESA Analysis

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

Refreshed Dietary Guidelines Shift Focus to Healthy Eating Patterns

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content